CA3237885A1 - Treatment of treatment resistant depression with psilocybin - Google Patents

Treatment of treatment resistant depression with psilocybin Download PDF

Info

Publication number
CA3237885A1
CA3237885A1 CA3237885A CA3237885A CA3237885A1 CA 3237885 A1 CA3237885 A1 CA 3237885A1 CA 3237885 A CA3237885 A CA 3237885A CA 3237885 A CA3237885 A CA 3237885A CA 3237885 A1 CA3237885 A1 CA 3237885A1
Authority
CA
Canada
Prior art keywords
psilocybin
dose
subject
weeks
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3237885A
Other languages
English (en)
French (fr)
Inventor
Trevor Anthony MILL
Guy Manning Goodwin
Joyce Tsai
Lindsey MARWOOD
Sunil Mistry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compass Pathfinder Ltd
Original Assignee
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Pathfinder Ltd filed Critical Compass Pathfinder Ltd
Publication of CA3237885A1 publication Critical patent/CA3237885A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3237885A 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin Pending CA3237885A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277407P 2021-11-09 2021-11-09
US63/277,407 2021-11-09
US202163284973P 2021-12-01 2021-12-01
US63/284,973 2021-12-01
PCT/US2022/048713 WO2023086252A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Publications (1)

Publication Number Publication Date
CA3237885A1 true CA3237885A1 (en) 2023-05-19

Family

ID=84799979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3237885A Pending CA3237885A1 (en) 2021-11-09 2022-11-02 Treatment of treatment resistant depression with psilocybin

Country Status (8)

Country Link
US (1) US20250000881A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429671A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543379A (cg-RX-API-DMAC7.html)
KR (1) KR20240110816A (cg-RX-API-DMAC7.html)
AU (1) AU2022387053A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237885A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005632A (cg-RX-API-DMAC7.html)
WO (1) WO2023086252A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2588505B (en) * 2017-10-09 2022-08-03 Compass Pathfinder Ltd Preparation of psilocybin
GB2571696B (en) * 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR20220008824A (ko) * 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.

Also Published As

Publication number Publication date
EP4429671A1 (en) 2024-09-18
KR20240110816A (ko) 2024-07-16
JP2024543379A (ja) 2024-11-21
MX2024005632A (es) 2024-07-29
WO2023086252A1 (en) 2023-05-19
US20250000881A1 (en) 2025-01-02
AU2022387053A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
AU2020259406B2 (en) Treatment of depression and other various disorders with psilocybin
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CA3240774A1 (en) Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
TW201242600A (en) Treatment of cognitive dysfunction in schizophrenia
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
HK40068334A (en) Treatment of depression and other various disorders with psilocybin
HK40068314A (en) Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241007

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006